<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369025">
  <stage>Registered</stage>
  <submitdate>15/09/2015</submitdate>
  <approvaldate>28/10/2015</approvaldate>
  <actrnumber>ACTRN12615001148561</actrnumber>
  <trial_identification>
    <studytitle>An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in ageing in healthy adults.</studytitle>
    <scientifictitle>An investigation of the effects of intranasal oxytocin spray on socio-emotional brain regions in ageing in healthy adults.</scientifictitle>
    <utrn>U1111-1172-7351</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nil - Healthy Ageing</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Studies of the normal brain and nervous system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two acute treatment (24 IU each) conditions including; a) intranasal placebo, and b) intranasal oxytocin (Syntocinon, Novartis, Switzerland). The two treatment conditions will be separated by a minimum of 1 week (washout period). The nasal sprays will be administered 50 mins prior to the functional magnetic resonance (fMRI) protocol using a standard supervised dosage procedure that involves 3 sprays in each the left or right nostril (6 sprays total). The fMRI protocol will be 20mins in duration and involve showing participants a brief task involving pictures of human faces expressing different emotions. The MRI protocol will also involve taking structural, resting state images of the brain while the participant is not engaged in a task.</interventions>
    <comparator>Placebo, a saline solution without the active (peptide) ingredient.
Young healthy adults (aged 18-39 years) will be compared to healthy older adults (60+ years)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Functional MRI (fMRI) data will be collected in response to an emotional face expression task. The fMRI data will be compared between the older and younger age groups for differences in brain response (e.g., in the amygdala) between placebo and oxytocin conditions.</outcome>
      <timepoint>The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Using the structural MRI data, the whole-brain structural differences n grey and white matter will be examined comparing the participants in the older and younger age groups  to see if any structural brain differences are present.</outcome>
      <timepoint>The data will be collected in the 50-80 min post drug administration and will be analysed post all data collection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Right-handed; non-smoker and no drug/alcohol abuse; medication free; no neurological disorders, and no metal objects present in body (or which can't be removed or which is not MRI safe). </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Clinically significant medical or neurological condition, significant head injury (or loss of consciousness from longer than 5 mins), presence of ferrous-containing metals within the body, inability to tolerate small enclosed spaces without anxiety.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>20/10/2015</actualstartdate>
    <anticipatedenddate>31/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Australian Catholic University Research</primarysponsorname>
    <primarysponsoraddress>Level 5, Mannix Building, Young St, Fitzroy, Vic, 3065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Australian Catholic University Research Fund</fundingname>
      <fundingaddress>Level 5, Mannix Building, Young St, Fitzroy, Vic, 3065</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The overall aim of the current study is to examine social and emotional brain regions involved in healthy ageing using a double-blind placebo controlled intranasal oxytocin design and MRI techniques involving fMRI.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Australian Catholic University HREC</ethicname>
      <ethicaddress>Level 5, Mannix Building, Young St, Fitzroy, Vic, 3065</ethicaddress>
      <ethicapprovaldate>10/10/2015</ethicapprovaldate>
      <hrec>2015-181H </hrec>
      <ethicsubmitdate>23/07/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/369025-2015-181H Ethics application approved!.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Izelle Labuschagne</name>
      <address>Level 5, Daniel Mannix Building, Young St, Fitzroy, VIC 3065
Locked Bag 4115, Fitzroy MDC, VIC 3065</address>
      <phone>+61 3 9953 3816 </phone>
      <fax />
      <email>izelle.labuschagne@acu.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sally Grace</name>
      <address>400B Burwood Road, Level 2
Swinburne University of Technology
Hawthorn, VIC 3122</address>
      <phone>+61 3 9214 8415</phone>
      <fax />
      <email>sgrace@swin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sally Grace</name>
      <address>400B Burwood Road, Level 2
Swinburne University of Technology
Hawthorn, VIC 3122</address>
      <phone>+61 3 9214 8415</phone>
      <fax />
      <email>sgrace@swin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Sally Grace</name>
      <address>400B Burwood Road, Level 2
Swinburne University of Technology
Hawthorn, VIC 3122</address>
      <phone>+61 3 9214 8415</phone>
      <fax />
      <email>sgrace@swin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>